Trained immunity provides a unifying framework linking innate immune memory to both protective and maladaptive inflammation ...
Artiva Biotherapeutics is developing NK cell immunotherapy for autoimmune disease. Early trial data in B-cell lymphoma ...
ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary ...
A historic corruption scandal simmered in plain sight for more than a year while the sport’s power structure chose indifference over integrity.
Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma: Raritan, New Jersey Friday, January 16, 2026, 10:00 Hrs [ ...
Investing.com -- ImmunityBio (NASDAQ:IBRX) stock surged 28% Thursday after the company reported preliminary 2025 net product ...
Researchers at the Buck Institute used Axiom-2 blood samples to show spaceflight temporarily accelerated epigenetic aging, ...
The US president vowed to ‘end childhood cancer’. But his administration is dismantling the search for a cure and sending families scrambling for treatment ...
For years, Europe lived with a quiet assumption: that no matter what happened elsewhere, stability would somehow hold. Wars ...
The MajesTEC-9 trial showed a 40% reduced risk of death and a 71% reduced risk of disease progression or death with ...
ImmunityBio (IBRX) stock rises as the company records over 400% YoY groiwth in Q4 net product revenue thanks to its cancer ...
Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback